Pemetrexed News and Research

RSS
EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

New discovery can provide insight into lung cancer

New discovery can provide insight into lung cancer

Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer

Phase III trial results: Erlotinib has comparable efficacy to chemotherapy with better tolerability against lung cancer

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

IASLC publishes new international multidisciplinary classification for lung adenocarcinoma

IASLC publishes new international multidisciplinary classification for lung adenocarcinoma

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

Threshold reports positive results from TH-302 Phase 1/2 clinical trial in pancreatic cancer

NIAID scientists confirm antiviral activity of two lead compounds against HPV

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

TRACON to present data on TRC105, TRC102 cancer therapies at EORTC-NCI-AACR Symposium

Threshold announces TH-302 Phase 1/2 clinical trial interim results

Threshold announces TH-302 Phase 1/2 clinical trial interim results

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

TTF therapy with chemotherapy increases survival time in patients with non-small cell lung cancer

TTF therapy with chemotherapy increases survival time in patients with non-small cell lung cancer

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

New clinical research findings on oncology to be highlighted at ASCO 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation